325 related articles for article (PubMed ID: 36273157)
21. Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma.
Zhou J; Toh SH; Tan TK; Balan K; Lim JQ; Tan TZ; Xiong S; Jia Y; Ng SB; Peng Y; Jeyasekharan AD; Fan S; Lim ST; Ong CJ; Ong CK; Sanda T; Chng WJ
Mol Cancer; 2023 Apr; 22(1):69. PubMed ID: 37032358
[TBL] [Abstract][Full Text] [Related]
22. Identification of PBK as a hub gene and potential therapeutic target for medulloblastoma.
Deng Y; Wen H; Yang H; Zhu Z; Huang Q; Bi Y; Wang P; Zhou M; Guan J; Zhang W; Li M
Oncol Rep; 2022 Jul; 48(1):. PubMed ID: 35593307
[TBL] [Abstract][Full Text] [Related]
23. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract][Full Text] [Related]
24. Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition.
Graziani V; Garcia AR; Alcolado LS; Le Guennec A; Henriksson MA; Conte MR
Sci Rep; 2023 Jan; 13(1):1273. PubMed ID: 36690651
[TBL] [Abstract][Full Text] [Related]
25. Active medulloblastoma enhancers reveal subgroup-specific cellular origins.
Lin CY; Erkek S; Tong Y; Yin L; Federation AJ; Zapatka M; Haldipur P; Kawauchi D; Risch T; Warnatz HJ; Worst BC; Ju B; Orr BA; Zeid R; Polaski DR; Segura-Wang M; Waszak SM; Jones DT; Kool M; Hovestadt V; Buchhalter I; Sieber L; Johann P; Chavez L; Gröschel S; Ryzhova M; Korshunov A; Chen W; Chizhikov VV; Millen KJ; Amstislavskiy V; Lehrach H; Yaspo ML; Eils R; Lichter P; Korbel JO; Pfister SM; Bradner JE; Northcott PA
Nature; 2016 Feb; 530(7588):57-62. PubMed ID: 26814967
[TBL] [Abstract][Full Text] [Related]
26. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
27. Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Pelish HE; Liau BB; Nitulescu II; Tangpeerachaikul A; Poss ZC; Da Silva DH; Caruso BT; Arefolov A; Fadeyi O; Christie AL; Du K; Banka D; Schneider EV; Jestel A; Zou G; Si C; Ebmeier CC; Bronson RT; Krivtsov AV; Myers AG; Kohl NE; Kung AL; Armstrong SA; Lemieux ME; Taatjes DJ; Shair MD
Nature; 2015 Oct; 526(7572):273-276. PubMed ID: 26416749
[TBL] [Abstract][Full Text] [Related]
28. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
29. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
[TBL] [Abstract][Full Text] [Related]
30. The LIN28B-let-7-PBK pathway is essential for group 3 medulloblastoma tumor growth and survival.
Shahab SW; Roggeveen CM; Sun J; Kunhiraman H; McSwain LF; Juraschka K; Kumar SA; Saulnier O; Taylor MD; Schniederjan M; Schnepp RW; MacDonald TJ; Kenney AM
Mol Oncol; 2023 Sep; 17(9):1784-1802. PubMed ID: 37341142
[TBL] [Abstract][Full Text] [Related]
31. Super-enhancers and novel therapeutic targets in colorectal cancer.
Liu Q; Guo L; Lou Z; Xiang X; Shao J
Cell Death Dis; 2022 Mar; 13(3):228. PubMed ID: 35277481
[TBL] [Abstract][Full Text] [Related]
32. An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate.
Zagozewski J; Shahriary GM; Morrison LC; Saulnier O; Stromecki M; Fresnoza A; Palidwor G; Porter CJ; Forget A; Ayrault O; Hawkins C; Chan JA; Vladoiu MC; Sundaresan L; Arsenio J; Taylor MD; Ramaswamy V; Werbowetski-Ogilvie TE
Nat Commun; 2020 Jul; 11(1):3627. PubMed ID: 32686664
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of CRX, a Group 3-specific oncogenic transcription factor, inhibits TGF-β/activin signaling in medulloblastoma cells.
Masurkar SA; Deogharkar A; Bharambe HS; Shirsat NV
Biochem Biophys Res Commun; 2021 Sep; 568():76-82. PubMed ID: 34192607
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional up-regulation of Gadd45a in Patched-associated medulloblastoma.
Kappler R; Hess I; Schlegel J; Hahn H
Int J Oncol; 2004 Jul; 25(1):113-20. PubMed ID: 15201996
[TBL] [Abstract][Full Text] [Related]
35. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.
Pezuk JA; Brassesco MS; de Oliveira RS; Machado HR; Neder L; Scrideli CA; Tone LG
Childs Nerv Syst; 2017 Apr; 33(4):609-615. PubMed ID: 28283778
[TBL] [Abstract][Full Text] [Related]
36. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma.
Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
[TBL] [Abstract][Full Text] [Related]
37. A therapeutically targetable positive feedback loop between lnc-HLX-2-7, HLX, and MYC that promotes group 3 medulloblastoma.
Katsushima K; Joshi K; Yuan M; Romero B; Batish M; Stapleton S; Jallo G; Kolanthai E; Seal S; Saulnier O; Taylor MD; Wechsler-Reya RJ; Eberhart CG; Perera RJ
Cell Rep; 2024 Mar; 43(3):113938. PubMed ID: 38460130
[TBL] [Abstract][Full Text] [Related]
38. Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma.
Martell E; Kuzmychova H; Kaul E; Senthil H; Chowdhury SR; Morrison LC; Fresnoza A; Zagozewski J; Venugopal C; Anderson CM; Singh SK; Banerji V; Werbowetski-Ogilvie TE; Sharif T
Nat Commun; 2023 May; 14(1):2502. PubMed ID: 37130865
[TBL] [Abstract][Full Text] [Related]
39. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
[TBL] [Abstract][Full Text] [Related]
40. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
